Abridged Curriculum Vitae
Full Name: Jordi Antón
Date of Birth: 3rd august 1968
Nationality: Spanish
Academic Title: Pediatrician, MD, PhD
Present Position (including name and address of the institution):
Senior Attendant. Pediatric Rheumatology Unit. Pediatrics Department.
Hospital Sant Joan de Deu
University of Barcelona.
Paaseig Sant Joan de Deu, 2. 08950 Esplugues (Barcelona)
Starting Date in this Position: September 2003
Relevant Professional Qualifications (Post Graduate Training):
Qualification Dates
Pediatrics 1994-1997
Pediatric rheumatology 1999-2000
Associate professor. University of Barcelona 2005-
Relevant Experience / Positions (Responsibility/Years):
Experience Dates
Pediatrics Departament. Hospital of Sabadell. Corporaciò Parc Taulí 1998-2003
President. Spanish Pediatric Rheumatology Society (SERPE) 2011-
Other relevant information (e.g. Publications, participation in International Conferences/Clinical Trials):
Dates
1: Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, Lehmberg K, Weitzman S, Insalaco A, Wouters C, Shenoi S, Espada G, Ozen S, Anton J, Khubchandani R, Russo R, Pal P, Kasapcopur O, Miettunen P, Maritsi D, Merino R, Shakoory B, Alessio M, Chasnyk V, Sanner H, Gao Y, Huasong Z, Kitoh T, Avcin T, Fischbach M, Frosch M, Grom A, Huber A, Jelusic M, Sawhney S, Uziel Y, Ruperto N, Martini A, Cron RQ, Ravelli A; on behalf of the Pediatric Rheumatology International Trials Organization; the Childhood Arthritis & Rheumatology Research Alliance; the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society. Clinical features, treatment and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis A multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014 Jul 30. doi: 10.1002/art.38802.
[Epub ahead of print]
2: Giménez-Roca C, Iglesias E, Torrente-Segarra V, Bou R, Sánchez-Manubens J, Calzada-Hernández J, Hernández S, Ricart S, Antón J. Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age. Rheumatol Int. 2014 Aug 3. [Epub ahead of print]
3: Baroja-Mazo A, Martín-Sánchez F, Gomez AI, Martínez CM, Amores-Iniesta J, Compan V, Barberà-Cremades M, Yagüe J, Ruiz-Ortiz E, Antón J, Buján S, Couillin I, Brough D, Arostegui JI, Pelegrín P. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol. 2014 Aug;15(8):738-48.
4: Bou R, Iglesias E, Antón J. Treatment of uveitis associated with juvenile
idiopathic arthritis. Curr Rheumatol Rep. 2014 Aug;16(8):437.
5: Hofer M, Pillet P, Cochard MM, Berg S, Krol P, Kone-Paut I, Rigante D, Hentgen V, Anton J, Brik R, Neven B, Touitou I, Kaiser D, Duquesne A, Wouters C, Gattorno M. International periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome cohort: description of distinct phenotypes in 301 patients. Rheumatology (Oxford). 2014 Jun;53(6):1125-9.
6: García-De-Vicuña C, Díaz-Llopis M, Salom D, Bou R, Díaz-Cascajosa J,
Cordero-Coma M, Ortega G, Ortego-Centeno N, Suarez-De-Figueroa M, Cruz-Martínez J, Fonollosa A, Blanco R, García-Aparicio ÁM, Benítez-Del-Castillo JM, Antón J. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm. 2013;2013:560632.
7: Sánchez-Manubens J, Bou R, Anton J. Diagnosis and classification of Kawasaki disease. J Autoimmun. 2014 Feb-Mar;48-49:113-7.
8. Nakagawa K, Gonzalez-Roca E, Souto A, Kawai T, Umebayashi H, Campistol JM, Cañellas J, Takei S, Kobayashi N, Callejas-Rubio JL, Ortego-Centeno N, Ruiz-Ortiz E, Rius F, Anton J, Iglesias E, Jimenez-Treviño S, Vargas C, Fernandez-Martin J, Calvo I, Hernández-Rodríguez J, Mendez M, Dordal MT, Basagaña M, Bujan S, Yashiro M, Kubota T, Koike R, Akuta N, Shimoyama K, Iwata N, Saito MK, Ohara O, Kambe N, Yasumi T, Izawa K, Kawai T, Heike T, Yagüe J, Nishikomori R, Aróstegui JI. Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by
different phenotypes of cryopyrin-associated periodic syndromes. Ann Rheum Dis. 2013 Dec 10. [Epub ahead of print]
9. Iglesias E, Torrente-Segarra V, Bou R, Ricart S, González MI, Sánchez J,
Calzada J, Antón J. Non-systemic juvenile idiopathic arthritis outcome after
reaching clinical remission with anti-TNF-α therapy: a clinical practice
observational study of patients who discontinued treatment. Rheumatol Int. 2013 Oct 26. [Epub ahead of print]
10: Pelegrín L, Casaroli-Marano R, Antón J, Carmen García de Vicuña M, Molina-Prat N, Ignacio Aróstegui J, Yagüe J, Ríos J, Adán A. Predictive Value of Selected Biomarkers, Polymorphisms, and Clinical Features for Oligoarticular Juvenile Idiopathic Arthritis-associated Uveitis. Ocul Immunol Inflamm. 2013 Oct 16. [Epub ahead of print].
11: Burns JC, Herzog L, Fabri O, Tremoulet AH, Rodó X, Uehara R, Burgner D, Bainto E, Pierce D, Tyree M, Cayan D; Kawasaki Disease Global Climate Consortium. Seasonality of Kawasaki disease: a global perspective. PLoS One. 2013 Sep 18;8(9):e74529.
12: Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L, Frenkel J, Anton J, Kone-Paut I, Cattalini M, Bader-Meunier B, Insalaco A, Hentgen V, Merino R, Modesto C, Toplak N, Berendes R, Ozen S, Cimaz R, Jansson A, Brogan PA, Hawkins PN, Ruperto N, Martini A, Woo P, Gattorno M; for the Paediatric Rheumatology International Trials Organisation (PRINTO), the EUROTRAPS and the Eurofever Project. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2013 Aug 21. [Epub ahead of print]
13: Bishop N, Adami S, Ahmed SF, Antón J, Arundel P, Burren CP, Devogelaer JP, Hangartner T, Hosszú E, Lane JM, Lorenc R, Mäkitie O, Munns CF, Paredes A, Pavlov H, Plotkin H, Raggio CL, Reyes ML, Schoenau E, Semler O, Sillence DO, Steiner RD. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Oct 26;382(9902):1424-32
14: Iglesias E, Jou C, Bou R, Antón J. [Importance of muscle biopsy in the
diagnosis of juvenile dermatomyositis]. An Pediatr (Barc). 2014 Feb;80(2):e25-6.
15: Sarrión P, Sangorrin A, Urreizti R, Delgado A, Artuch R, Martorell L,
Armstrong J, Anton J, Torner F, Vilaseca MA, Nevado J, Lapunzina P, Asteggiano CG, Balcells S, Grinberg D. Mutations in the EXT1 and EXT2 genes in Spanish patients with multiple osteochondromas. Sci Rep. 2013;3:1346.
16: Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, Rabinovich E, Riebschleger M, Antón J, Blier PR, Gerloni V, Hazen MM, Kessler E, Onel K, Passo MH, Rennebohm RM, Wallace CA, Woo P, Wulffraat N; Childhood Arthritis Rheumatology Research Alliance Carra Net Investigators. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013 May;65(5):745-52.
17: Dolezalova P, Price-Kuehne FE, Özen S, Benseler SM, Cabral DA, Anton J, Brunner J, Cimaz R, O'Neil KM, Wallace CA, Wilkinson N, Eleftheriou D, Demirkaya E, Böhm M, Krol P, Luqmani RA, Brogan PA. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis. 2013 Oct;72(10):1628-33.
18: Ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C, Koné-Paut I, Cantarini L, Insalaco A, Neven B, Hofer M, Rigante D, Al-Mayouf S, Touitou I, Gallizzi R, Papadopoulou-Alataki E, Martino S, Kuemmerle-Deschner J, Obici L, Iagaru N, Simon A, Nielsen S, Martini A, Ruperto N, Gattorno M, Frenkel J; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever/Eurotraps Projects. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013 May;72(5):678-85.
19: Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, Wulffraat N, Wedderburn L, Stanevicha V, Mihaylova D, Harjacek M, Len C, Toppino C, Masi M, Minden K, Saurenmann T, Uziel Y, Vesely R, Apaz MT, Kuester RM, Elorduy MJ, Burgos-Vargas R, Ioseliani M, Magni-Manzoni S, Unsal E, Anton J, Balogh Z, Hagelberg S, Mazur-Zielinska H, Tauber T, Martini A, Foell D; Paediatric Rheumatology International Trials Organization (PRINTO). Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis. 2012 Dec; 71(12): 1991-7..
20: Heiligenhaus A, Foeldvari I, Edelsten C, Smith JR, Saurenmann RK, Bodaghi B, de Boer J, Graham E, Anton J, Kotaniemi K, Mackensen F, Minden K, Nielsen S, Rabinovich EC, Ramanan AV, Strand V; Multinational Interdisciplinary Working Group for Uveitis in Childhood. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken). 2012 Sep;64(9):1365-72.
21: Márquez Balbás G, González-Enseñat MA, Vicente A, Creus-Vila L, Antón J, Umbert-Millet P. Incontinentia pigmenti and bipolar aphthosis: an unusual
combination. ISRN Dermatol. 2011;2011:814186.
22: Antón J. [Autoinflammatory syndromes]. Med Clin (Barc). 2011 Jan;136 Suppl 1:3-9.
23: Koné-Paut I, Darce-Bello M, Shahram F, Gattorno M, Cimaz R, Ozen S, Cantarini L, Tugal-Tutktun I, Assaad-Khalil S, Hofer M, Kuemmerle-Deschner J, Benamour S, Al Mayouf S, Pajot C, Anton J, Faye A, Bono W, Nielsen S, Letierce A, Tran TA; PED-BD International Expert Committee. Registries in rheumatological and musculoskeletal conditions. Paediatric Behçet's disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford). 2011 Jan;50(1):184-8.
24: Modesto C, Antón J, Rodriguez B, Bou R, Arnal C, Ros J, Tena X, Rodrigo C, Rotés I, Hermosilla E, Barceló P. Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scand J Rheumatol. 2010 Nov;39(6):472-9.
25: Ruperto N, Ozen S, Pistorio A, Dolezalova P, Brogan P, Cabral DA, Cuttica R, Khubchandani R, Lovell DJ, O'Neil KM, Quartier P, Ravelli A, Iusan SM, Filocamo G, Magalhães CS, Unsal E, Oliveira S, Bracaglia C, Bagga A, Stanevicha V, Manzoni SM, Pratsidou P, Lepore L, Espada G, Kone-Paut I, Zulian F, Barone P, Bircan Z, Maldonado Mdel R, Russo R, Vilca I, Tullus K, Cimaz R, Horneff G, Anton J, Garay S, Nielsen S, Barbano G, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura,
childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Ann Rheum Dis. 2010 May;69(5):790-7.
26: Moorthy LN, Peterson MG, Baratelli M, Hassett AL, Lehman TJ; International SMILEY Collaborative Group. Preliminary cross-cultural adaptation of a new pediatric health-related quality of life scale in children with systemic lupus erythematosus: an international effort. Lupus. 2010 Jan;19(1):83-8.
27: Serrano M, Ormazábal A, Antón J, Aróstegui JI, García-Cazorla A.
Cerebrospinal fluid neopterin and cryopyrin-associated periodic syndrome. Pediatr Neurol. 2009 Dec;41(6):448-50.
28: Marín-Valencia I, Antón J, Ros J, Cols M. Severe generalized oedema with
haemodynamic instability in a previously healthy patient (Case Presentation).
Acta Paediatr. 2009 Mar;98(3):420, 600-1.
29: von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, Chrabieh M, Mustapha IB, Ghandil P, Camcioglu Y, Vasconcelos J, Sirvent N, Guedes M, Vitor AB, Herrero-Mata MJ, Aróstegui JI, Rodrigo C, Alsina L, Ruiz-Ortiz E, Juan M, Fortuny C, Yagüe J, Antón J, Pascal M, Chang HH, Janniere L, Rose Y, Garty BZ, Chapel H, Issekutz A, Maródi L, Rodriguez-Gallego C, Banchereau J, Abel L, Li X, Chaussabel D, Puel A, Casanova JL. Pyogenic bacterial infections in humans with MyD88 deficiency. Science. 2008 Aug 1;321(5889):691-6.
30: de Carpi JM, Castejón E, Masiques L, Vilar P, Antón J, Varea V.
Gastrointestinal involvement in pediatric polyarteritis nodosa. J Pediatr
Gastroenterol Nutr. 2007 Feb;44(2):274-8.
31: Mou SS, Punaro L, Antón J, Luckett PM. Severe systemic hypersensitivity
reaction to ibuprofen: a presentation of systemic lupus erythematosus. J
Rheumatol. 2006 Jan;33(1):171-2.
32: Ozen S, Anton J, Arisoy N, Bakkaloglu A, Besbas N, Brogan P, García-Consuegra J, Dolezalova P, Dressler F, Duzova A, Ferriani VP, Hilário MO, Ibáñez-Rubio M, Kasapcopur O, Kuis W, Lehman TJ, Nemcova D, Nielsen S, Oliveira SK, Schikler K, Sztajnbok F, Terreri MT, Zulian F, Woo P. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004 Oct;145(4):517-22.
Estudio multicéntrico, aleatorizado, de grupos paralelos, controlado con placebo, doble ciego para evaluar la seguridad, eficacia y farmacocinética de belimumab, un anticuerpo monoclonal humano anti-BLyS, más terapia estándar en pacientes pediátricos con lupus eritematoso sistémico (LES)
Promotor: GlaxoSmithKline S.A.
Código del protocolo: BEL114055
Función: Investigador Principal
“Estudio fase III, multicéntrico, abierto, para evaluar la farmacocinética, eficacia y seguridad de abatacept administrado por vía subcutánea (s.c.) en niños y adolescentes con artritis idiopática juvenil poliarticular (AIJp) activa y respuesta inadecuada (RI) a fármacos antirreumáticos modificadores de enfermedad (FAME) biológicos o no biológicos”
Promotor: Bristol- Myers-Squibb
Códigodel protocolo: IM101-301
Función: Investigador Principal
“Estudio de fase Ib, multicéntrico, abierto, para investigar la farmacocinética, farmacodinamia y seguridad de tocilizumab tras administración subcutánea a pacientes con artritis idiopática juvenil poliarticular”
Promotor: Roche
Código del protocolo: WA28117
Función: Investigador Principal
SHARE: Single Hub and access point for Paediatric Rheumatology in Europe
Entidad financiadora: SANCO 2011, section 3.2.3.3, FP7 call 2011 Second Programme of Community action in the field of Health (2008-2013). Executive Agency for Health and Consumers, EAHC (European Union)
Duración: 2012-2015
Financiación (en miles de euros): 860.244 euros
Investigador: colaborador
Incidencia de mutaciones somáticas del gen NLRP3 en pacientes con diagnóstico clínico compatible con síndromes periódicos asociados a la criopirina
Función: Investigador Principal
Agencia financiadora: Beca Sociedad Catalana de Reumatología
Financiación: 6000 euros
Duración: Junio 2012-Junio 2014
EPOCA (EPidemiology, treatment and Outcome of Childhood Arthritis)
Función: Investigador Principal Hospital Sant Joan de Déu
Agencia financiadora: PRINTO (Pediatric Rheumatology Trials Organization)
Duración: 2011-2014
Evaluation of Early Treatment in Children With Juvenile Idiopathic Arthritis: A Retrospective Analysis
Función: Investigador Principal
Agencia Financiadora: Pfizer
Financiación: 55.413 €
Duración: 2011-2013
PHARMACHILD - Long-term PHARMacovigilance for Adverse effects in Childhood arthritis focussing on Immune modulatory drugs a Pediatric Rheumatology Trials Organization (PRINTO) / Pediatric Rheumatology European Society (PRES) registry
Función: Investigador Principal Hospital Sant Joan de Déu
Agencia Financiadora: FP7- HEALTH-2010-single-stage. EU grant (2011-2014): (project number 260353)
Financiación: 3.920.000 € (2.970.000€ funded by FP7)
Duración: 2011-2014 (36 months)
Study CACZ885G2305. A randomized , double blind, placebo controlled, single-dose study to assess the initial efficacy of canakinumab (ACZ885) with respect to the adapted ACR pediatric 30 criteria in patients with Systemic Juvenil Idiopathic Arthritis(SJIA) and active systemic manifestations.
Financiación: Novartis.
Investigador: Principal
Duración: 2009-2010
Study CACZ885G2301. A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations.
Financiación: Novartis.
Investigador: Principal
Duración: 2009-2010
Study CACZ885G2301E1. An open label study of canakinumab (ACZ885) in patients with Systemic Juvenile idiopathic arthritis (SJIA) and active systemic manifestations.
Financiación: Novartis.
Investigador: Principal
Duración: 2009-2012
CLIPPER. A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis.
Financiación: Wyeth- Pfizer.
Investigador: Principal
Duración: 2010-2012
STRIVE. Long-term, Multi-center, Longitudinal Post-marketing, Observational Registry to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children with Moderate to Severe Active Polyarticular or Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Financiación: Abbott.
Investigador: Principal
Duración: 2010-2020
Estudio piloto, abierto, multicéntrico, de eficacia y seguridad del tratamiento con canakinumab duranet 6 meses y seguimiento de hasta 6 meses, en pacientes con síndrome Hiper-IgD activo.
Financiación: Novartis.
Investigador: Principal
Duración: 2011-2012.
INternational CHildhood ARthritis GEntics (INCHARGE) Consortium: A Genome Wide Association Study of Childhood Arthritis.
Función: Investigador Principal Hospital Sant Joan de Déu
Agencia financiadora: Arthritis Research campaign: ARC grant reference 17552.
Duración: 2008-(sin limite en la actualidad)
Número de Proyecto: PI06/0241
The PRES European Network of Registries for Autoinflammatory Diseases in childhood: EuroFever Project
Función: Investigador principal Hospital Sant Joan de Déu
Agencia Financiadora: Agency for Health and Cosnumers EAHC, Project Nº 2007332)
Financiación: 341.733,46 €
Duración: 2008-2011(36 meses)
Estudio de correlación entre los factores clínicos y polimorfismos genéticos para el desarrollo y severidad de la uveítis asociada a la artritis idiopática juvenil (AIJ).
Función: Investigador Principal Hospital Sant Joan de Déu
Agencia financiadora: Hospital Clinic - Hospital Sant Joan de Déu
Duración: 2008-2011
Phase III. A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of One year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate (risedronate sodium), in Children > 4 to < 16 Years Old with Osteogenesis Imperfecta. 2006
Función: Investigador Principal Hospital Sant Joan de Déu
Agencia Financiadora: Warner Chilcott - Procter and Gamble - Sanofi-Aventis
Duración: 3 años (2006-2010)
Cross cultural validation of a novel quality of life scale for pediatric lupus - proposal and update
Función: Investigador Principal Hospital Sant Joan de Déu
Agencia Financiadora: UMDNJ Foundation Grant 2004-2005; Pfizer Clinical Scholar Research Award 2005-2007; Arthritis Foundation Investigator Award 2007-2009; CARRA
Duración: 4 años (2006-2009)
Número de Proyecto: PS09/01182
Título: Análisis de las vías de señalización Toll/IL-1 receptor (TIR), Nod-like receptor (NLR) y NF-κB en las formas hereditarias y no hereditarias de las enfermedades autoinflamatorias. Valoración de su utilidad clínica como pruebas predictivas de respuesta a terapias biológicas.
Entidad financiadora: Fondo de Investigaciones Sanitarias
Duración: 2010-2012
Centro: Hospital Clínic de Barcelona - Hospital Sant Joan de Déu
Investigador principal: Jordi Yagüe Ribes
Investigador: Colaborador
Phase III. A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of One year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate (risedronate sodium), in Children > 4 to < 16 Years Old with Osteogenesis Imperfecta. 2006
Obejtivos: Valoración de la seguridad y eficacia del tratamiento con risedronatoen pacientes con Osteiogénesis Imperfecta
Finaciación: Industria farmaceutica
Centro: Multicéntrico Internacional
Investigador: colaborador
Duración: 3 años (2006-2010)
Número de Proyecto: PI06/0241
Título: Análisis de las bases moleculares responsables de las enfermedades autoinflamatorias sistémicas no filiadas: desarrollo y validación de pruebas diagnósticas e identificación de potenciales dianas para terapias biológicas inmunomoduladoras.
Entidad financiadora: Fondo de Investigaciones Sanitarias
Duración: 2007-2009
Centro: Hospital Clínic de Barcelona - Hospital Sant Joan de Déu
Investigador principal: Jordi Yagüe Ribes
Investigador: Colaborador
Cross cultural validation of a novel quality of life scale for pediatric lupus – proposal and update
Objetivos: validación de una escala clínica para la valoración de la calidad de vida en pacientes con Lupus
Financiación: No
Centro: Multicéntrico Internacional
Investigador: colaborador
Duración: 4 años (2006-2009)
A randomised trial of 6 months versus 12 months withdrawal of methotrexate (MTX) in patients with juvenile idiopathic arthritis (JIA) in clinical remission
Objetivos: Valorar la duración de la remisión clínica tras la retirada del metotrexate a los 6 meses o a los 12 meses en pacientes con Artritis Idiopática Juvenil
Financiación: PRINTO (Pediatric Rheumatology Trials Organization)
Centro: Multicéntrico Internacional
Investigador: Colaborador
Duración: 3 años (2006-2008)
Artritis inflamatòries de la infància: estudi prospectiu de la seva incidència i prevalença a Catalunya
Objetivo principal: Conocer la incidencia y prevalencia de las artritis inflamatorias en la infancia en Catalunya
Finaciación: Beca Marató de TV3
Centro: Hospital Vall d'Hebron - Hospital Sant Joan de Déu
Investigador: Colaborador
Duración: 3 años (2004-2007)
Inception cohort for early juvenile systemic sclerosis
Objetivos: Creation of a minimal gold standard for avalauation of patients with juvenile systemic sclerosis
Financiación. No
Centro: Multicéntrico internacional
Investigador: Colaborador
Date full C.V. last updated: August 29th 2014
This abridged C.V. represents an accurate summary of my current C.V.
Signature of Investigator Date: August 29th 2014